Tier 2 — strong

Multi-omics characterization of improved cognitive functions in Parkinson's disease patients after the combined metabolic activator treatment: a randomized, double-blinded, placebo-controlled phase II trial

Yulug B, Altay O, Li X, Hanoglu L, Cankaya S, Velioglu HA, Lam S, Yang H, Coskun E, Idil E, Bayraktaroglu Z, Nogaylar R, Ozsimsek A, Yildirim S, Bolat I, Kiliclioglu M, Bayram C, Yuksel N, Tozlu OO, Arif M, Shoaie S, Hacimuftuoglu A, Zhang C, Nielsen J, Turkez H, Borén J, Uhlén M, Mardinoglu A
Brain communications 2025 7; 1; fcae478

Bibliography

PubMed
PMID 39816194
PubMed Central
PMC11733689
DOI
10.1093/braincomms/fcae478
Funding
ScandiBio Therapeutics, Knut and Alice Wallenberg Foundation and EU research support; ChromaDex supplied NR.
Competing interests
Three authors were founders and shareholders of ScandiBio Therapeutics.

Study snapshot

DesignRandomized controlled study of a multi-ingredient or combined intervention
ModelHuman participants
Sample48 randomized: 32 combination and 16 placebo
InterventionNR, serine, NAC and carnitine tartrate; NR 1 g per combination dose
Duration84 days; once daily initially, then twice daily
EndpointsMotor scores; cognition; imaging and metabolic measures

What the study showed, in plain terms

The combination did not improve the principal motor outcomes; the report described selected cognition, network-imaging and metabolic signals.

Key findings

The combination did not improve the principal motor outcomes; the report described selected cognition, network-imaging and metabolic signals.

What this study can and cannot tell us

NR cannot be isolated from the other ingredients. The abstract contains inconsistent direction wording for cognitive scores, so numerical cognitive claims require the full tables.

Related papers in the corpus

Tier 2
Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial
Yulug B et al. · Translational neurodegeneration · 2023
Tier 2
The acute effect of different NAD + precursors included in the combined metabolic activators
Li X et al. · Free radical biology & medicine · 2023
Tier 2
Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19
Altay O et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
Tier 2
Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients
Zeybel M et al. · Molecular systems biology · 2021

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology